RecruitingPhase 2NCT07405554

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

Effect of Zinc Supplementation on Botulinum Toxin for Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Trial


Sponsor

Endeavor Health

Enrollment

72 participants

Start Date

Feb 26, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized, double-blind, placebo-controlled trial evaluates whether oral zinc plus phytase supplementation modifies clinical response to intradetrusor botulinum toxin injection in patients with overactive bladder. Participants will receive either zinc plus phytase supplementation or matching placebo for five days prior to intradetrusor botulinum toxin injection. Participants will be followed for six months after treatment to assess need for repeat botulinum toxin injection, urinary symptoms, and patient-reported outcomes related to overactive bladder.


Eligibility

Sex: FEMALEMin Age: 21 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Zinc Citrate Oral Capsule for people with overactive bladder (oab). The study is currently recruiting participants at 1 location. People eligible for this study include women aged 21 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGZinc Citrate Oral Capsule

Zinc citrate 50mg combined with 7,500 phytase units in an oral capsule

DRUGPlacebo

Placebo oral capsule


Locations(1)

Endeavor Health

Skokie, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07405554


Related Trials